SCHEMBL23999945

SCHEMBL23999945

Cc1cc(Nc2ccc(C=O)cn2)c2cc(N3CCOCC3)ccc2n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KMT2A Q03164 3/20 0.52
POLB P06746 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ACVR1 Q04771 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999554 0.86 MAPT (0.67) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL23999949 0.85 MAPKAPK2 (0.52) MAPTMAPK1ACVR1
SCHEMBL23999882 0.81 MAPT (0.60) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL23999923 0.77 MAPT (0.60) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL23999941 0.76 MAPKAPK2 (0.52) SMN1; SMN2KDM4EALDH1A1ACVR1
SCHEMBL23999903 0.76 MAPT (0.51) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL14587990 0.74 MAPT (0.58) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL25826542 0.74 MAPT (0.51) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL23999410 0.73 MAPT (0.56) MAPTKMT2APOLBSMN1; SMN2TSHR
SCHEMBL23999887 0.72 MAPT (0.59) MAPTKMT2APOLBSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPT 3962/4885KMT2A 3925/4885POLB 2552/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPT 3999/4885KMT2A 3974/4885POLB 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.